Search

Search Results

• 24 | IXEKIZUMAB WITH OR WITHOUT TIRZEPATIDE IN ADULTS WITH PSORIASIS AND OVERWEIGHT OR OBESITY: THE TOGETHER-PSO PHASE 3B RANDOMIZED CLINICAL TRIAL E. Filippi¹, M. Lebwohl², A. Blauvelt³, C. Kartman⁴, C. Leatherwood⁴, K. Gordon⁵, N. Sattar⁶, L. Puig⁷, J. Merola⁸, K. Siu⁴, R. Wang⁴, L. Sun⁴, A. Leung⁹, N. Somani⁴, M. Rueda⁴, A. Cardoso⁴, M. Genovese⁴, A. Armstrong¹⁰, B. Strober¹¹ | ¹Eli Lilly Italy S.p.A, Sesto Fiorentino, Italy; ²Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; ³Blauvelt Consulting, LLC, Annapolis, MD, USA; ⁴Eli Lilly and Company, Indianapolis, IN, USA; ⁵Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA; ⁶School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK; ⁷Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona School of Medicine, Barcelona, Spain; ⁸Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O’Donnell School of Public Health, Dallas, TX, USA; ⁹Syneos Health, Morrisville, NC, USA; ¹⁰Division of Dermatology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA; ¹¹Department of Dermatology, Yale University School of Medicine, New Haven, CT, Central Connecticut Dermatology Research, Cromwell, CT, USA

  Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica

  24-09-2026

  https://doi.org/10.4081/dr.2026.11086

  0

  PDF: 0

• 26 | CONCOMITANT THERAPY WITH IXEKIZUMAB PLUS TIRZEPATIDE IN ADULTS WITH PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY DEMONSTRATED SUPERIOR DISEASE CONTROL COMPARED TO IXEKIZUMAB ALONE: RESULTS FROM THE PH3B TOGETHER-PSA TRIAL E. Filippi¹, J. F. Merola², P. Mease³, A. Kivitz⁴, N. Sattar⁵, L. C. Coates⁶, C. E. Kartman⁷, P. Fischer⁷, L. Sun⁷, A. Cardoso⁷, M. C. Genovese⁷, A. Ogdie⁸ | ¹Eli Lilly Italia S.p.A, Florence, Italy; ²Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O’Donnell School of Public Health, Dallas, TX, USA; ³Providence Swedish Medical Center, Seattle, WA, USA; ⁴Altoona Center for Clinical Research, Duncansville, PA, USA; ⁵School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK; ⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; ⁷Eli Lilly and Company, Indianapolis, IN, USA; ⁸Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

  Associazione Dermatologi-Venereologi Ospedalieri Italiani e della Sanità Pubblica

  24-09-2026

  https://doi.org/10.4081/dr.2026.11088

  0

  PDF: 0